These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35176933)

  • 1. Outcomes of a complementary and alternative medicine based on vitamins, herbal products, and amino acid as a first line treatment in idiopathic overactive bladder syndrome in men and women without bladder outlet obstruction.
    Morselli S; Gemma L; Liaci A; Campi R; Serni S; Li Marzi V
    Urologia; 2022 Aug; 89(3):358-362. PubMed ID: 35176933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, multicenter, controlled study, comparing efficacy and safety of a new complementary and alternative medicine (CAM) versus Solifenacin Succinate in women with overactive bladder syndrome.
    Vecchioli-Scaldazza C; Morosetti C; Maruccia S; Casellato S; Rociola W; Illiano E; Garofalo F
    Arch Ital Urol Androl; 2017 Dec; 89(4):296-300. PubMed ID: 29473382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
    Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
    Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamsulosin plus a new complementary and alternative medicine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a retrospective comparative study.
    Fusco F; Creta M; Trama F; Esposito F; Crocetto F; Aveta A; Mangiapia F; Imbimbo C; Capece M; La Rocca R; Mirone V; Longo N
    Arch Ital Urol Androl; 2020 Oct; 92(3):. PubMed ID: 33016038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
    Villacampa F; Ruiz MA; Errando C; Arlandis S; Arumí D; Lizarraga I; Rejas J
    Int Urogynecol J; 2013 Apr; 24(4):573-81. PubMed ID: 23111865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OnabotulinumtoxinA detrusor injection improves female sexual function in women with overactive bladder wet syndrome.
    Balzarro M; Rubilotta E; Braga A; Bassi S; Processali T; Artibani W; Serati M
    Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():228-231. PubMed ID: 29753213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality?
    Schiavi MC; Sciuga V; Giannini A; Vena F; D'oria O; Prata G; Di Tucci C; Savone D; Aleksa N; Capone C; Di Mascio D; Meggiorini ML; Monti M; Zullo MA; Muzii L; Benedetti Panici P
    Gynecol Endocrinol; 2018 Aug; 34(8):666-669. PubMed ID: 29463148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy.
    Russo E; Misasi G; Montt-Guevara MM; Giannini A; Simoncini T
    Climacteric; 2023 Jun; 26(3):284-288. PubMed ID: 36912363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
    Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
    Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Fermented Red Clover Isoflavones in the Treatment of Overactive Bladder in Postmenopausal Women: A Randomized, Double-Blinded, Placebo-Controlled Trial.
    Villadsen AB; Holm-Jacobsen JN; Prabhala BK; Bundgaard-Nielsen C; Huntjens P; Kornum JB; Glavind K; Leutscher PDC; Christensen LP; Jeppesen PB; Sørensen S; Arenholt LTS
    Nutrients; 2023 Sep; 15(19):. PubMed ID: 37836449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
    Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumí D; Lizarraga I; Rejas J
    Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
    Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
    Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary incontinence, overactive bladder, and quality of life in women submitted to total hip replacement.
    Martines GA; Tamanini JTN; Mota GMDS; Barreto ET; Santos JLF; Sartori MGF; Girão MJBC; Castro RA
    Neurourol Urodyn; 2022 Mar; 41(3):830-840. PubMed ID: 35114028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is urodynamic evaluation able to change and improve the management of women with idiopathic overactive bladder?
    Serati M; Cantaluppi S; Coluccia AC; Scancarello C; Cimmino C; Braga A; Salvatore S; Finazzi Agrò E; Ghezzi F
    Minerva Urol Nephrol; 2021 Dec; 73(6):823-830. PubMed ID: 32573171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
    Lai H; Gardner V; Vetter J; Andriole GL
    BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urogynecological survey in a group of Italian women treated for overactive bladder: Symptoms and quality of life analysis during the Covid-19 period.
    Schiavi MC; Zullo MA; Luffarelli P; Di Pinto A; Oliva C; Palazzetti P
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):674-678. PubMed ID: 34247805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2019 Apr; 11(2):O180-O185. PubMed ID: 30565417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.